Clinical and Experimental Reproductive Medicine

The Korean Society for Reproductive Medicine (대한생식의학회)
권호 표지

Sequential use of Intramuscular and Oral Progesterone for Luteal Phase Support in in vitro Fertilization

체외수정시술 환자에서 황체기 보강 시 근주 투여와 경구 투여의 연속적 이용

  • Kim, Sang-Don (Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital) ;
  • Jee, Byung-Chul (Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital) ;
  • Lee, Jung-Ryeol (Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital) ;
  • Suh, Chang-Suk (Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital) ;
  • Kim, Seok-Hyun (Department of Obstetrics and Gynecology, College of Medicine, Seoul National University) ;
  • Moon, Shin-Yong (Department of Obstetrics and Gynecology, College of Medicine, Seoul National University)
  • 김상돈 (분당서울대학교병원 산부인과) ;
  • 지병철 (분당서울대학교병원 산부인과) ;
  • 이정렬 (분당서울대학교병원 산부인과) ;
  • 서창석 (분당서울대학교병원 산부인과) ;
  • 김석현 (서울대학교 의과대학 산부인과학교실) ;
  • 문신용 (서울대학교 의과대학 산부인과학교실)
  • Published : 2010.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: The aim of this study was to assess appropriate time to convert intramuscular progesterone support to oral administration for luteal phase support in in vitro fertilization (IVF). Methods: Seventy-six cycles of IVF in which fetal heart beat was identified after treatment were included. Patients underwent controlled ovarian hyperstimulation with GnRH agonist long protocol (n=7) or GnRH antagonist protocol (n=66). Cryopreserved embryo transfer was performed in three cycles. Luteal support was initiated by daily intramuscular injection of progesterone, and after confirmation of fetal heart beat, converted to oral micronized progesterone (Utrogestan, Laboratoires Besins International, France) 300 mg daily before or after 8 gestational weeks. The oral progesterone was continued for 11 weeks. Results: Overall clinical abortion rate was 3.9% (3/76) and mean time to conversion was $8^{+4}$ gestational weeks ($46{\pm}5.8$ days after oocytes retrieval). The abortion rate was 5.6% (1/17) and 3.4% (2/59) in patients with conversion before 7 weeks and after 8 weeks, respectively, which were not statistically significant (p=0.678). The miscarriages were occurred at $9^{+4}$ weeks, $11^{+3}$ weeks and $11^{+4}$ weeks. Conclusion: Sequential luteal support using intramuscular and oral progesterone yields a relatively low clinical abortion rate. If fetal heart beat confirmed, sequential regimen appears to be safe and convenient method to reduce patients' discomfort induced by multiple injections.

목 적: 체외수정시술 시 황체기 보강은 근주, 경질, 경구 등의 다양한 방법으로 이루어지고 있는데, 경구 투여법은 환자의 순응도가 높고 비교적 안전한 방법이다. 본 연구에서는 황체기 보강을 근주로 시작하여 경구 투여로 전환하는 방법의 효용성과 전환 시기에 따른 결과를 비교 분석하고자 하였다. 연구방법: 2003년 9월부터 2009년 6월까지 분당서울대학교병원에서 체외수정시술을 시행받은 환자에서 배아 이식 후 태아 심박동까지 확인된 76주기를 대상으로 하였다. 과배란유도는 GnRH agonist long protocol (n=7) 또는 GnRH antagonist protocol (n=66)을 이용하였으며 3주기에서는 냉동배아 이식을 시행하였다. 황체기 보강을 위하여 난자 채취일부터 매일 progest in oil 50 mg을 근주하였고, 태아 심박동이 확인된 후 임신 6~7주 (n=17) 또는 8주 이후 (n=59)에 micronized progesterone (Utrogestan, Laboratoires Besins International, France) 300 mg을 매일 경구로 투여하였다. 결 과: 대상군 전체의 유산율은 3.9% (3/76)이었으며, 경구 투여 전환시의 임신 주수는 평균 8주 4일 (난자 채취일로부터 $46{\pm}5.8$일)이었다. 황체기 보강을 임신 6~7주 사이에 경구 투여로 전환한 17주기 중에서 1례의 자연유산이 확인되었으며 유산 시 주수는 9주 4일이었다. 8주 이후에 경구 투여로 전환한 59주기 중에서는 2례의 자연유산이 확인되었으며 (11주 3일, 11주 4일), 두 군의 자연유산율은 각각 5.6%와 3.4%로 두 군 간에 통계적으로 유의한 차이는 없었다 (p=0.678). 결 론: 체외수정시술 후 황체기 보강을 시행하는 경우 태아 심박동이 확인된 이후에 근주 투여를 경구 투여로 전환하는 방법은 비교적 낮은 유산율을 보임을 확인하였으며, 특히 8주 이전에 전환하는 것도 유용한 방법이라 사료된다.

Keywords

References

  1. Penzias AS. Luteal phase support. Fertil Steril 2002; 77: 318-23. https://doi.org/10.1016/S0015-0282(01)02961-2
  2. Csapo AI, Pulkkinen MO, Kaihola HL. The relationship between the timing of luteectomy and the incidence of complete abortions. Am J Obstet Gynecol 1974; 118: 985-9. https://doi.org/10.1016/0002-9378(74)90671-1
  3. Csapo AI, Pulkkinen MO, Wiest WG. Effects of luteectomy and progesterone replacement therapy in early pregnant patients. Am J Obstet Gynecol 1973; 115: 759-65. https://doi.org/10.1016/0002-9378(73)90517-6
  4. Fatemi HM, Popovic-Todorovic B, Papanikolaou E, Donoso P, Devroey P. An update of luteal phase support in stimulated IVF cycles. Hum Reprod Update 2007; 13: 581-90. https://doi.org/10.1093/humupd/dmm021
  5. Aboulghar M. Luteal support in reproduction: when, what and how? Curr Opin Obstet Gynecol 2009 Jun; 21: 279-84. https://doi.org/10.1097/GCO.0b013e32832952ab
  6. Bergeron C. Morphological changes and protein secretion induced by progesterone in the endometrium during the luteal phase in preparation for nidation. Hum Reprod 2000; 15 Suppl 1: 119-28. https://doi.org/10.1093/humrep/15.suppl_1.119
  7. Szekeres-Bartho J, Balasch J. Progestagen therapy for recurrent miscarriage. Hum Reprod Update 2008; 14: 27-35.
  8. Pritts EA, Atwood AK. Luteal phase support in infertility treatment: a metaanalysis of the randomized trials. Hum Reprod 2002; 17: 2287-99. https://doi.org/10.1093/humrep/17.9.2287
  9. Daya S, Gunby J. Luteal phase support in assisted reproduction cycles. Cochrane Database Syst Rev 2004: CD004830.
  10. Propst AM, Hill JA, Ginsburg ES, Hurwitz S, Politch J, Yanushpolsky EH. A randomized study comparing crinone 8% and intramuscular progesterone supplementation in in vitro fertilizationembryo transfer cycles. Fertil Steril 2001; 76: 1144-9. https://doi.org/10.1016/S0015-0282(01)02872-2
  11. Anserini P, Costa M, Remorgida V, Sarli R, Guglielminetti E, Ragni N. Luteal phase support in assisted reproductive cycles using either vaginal (crinone 8%) or intramuscular (prontogest) progesterone: results of a prospective randomized study. Minerva Ginecol 2001; 53: 297-301.
  12. Abate A, Perino M, Abate FG, Brigandì A, Costabile L, Manti F. Intramuscular versus vaginal administration of progesterone for luteal phase support after in vitro fertilization and embryo transfer. A comparative randomized study. Clin Exp Obstet Gynecol 1999; 26: 203-6.
  13. Yanushpolsky E, Hurwitz S, Greenberg L, Racowsky C, Hornstein MD. Comparison of crinone 8% intravaginal gel and intramuscular progesterone supplementation for in vitro fertilization/embryo transfer in women under age 40: interim analysis of a prospective randomized trial. Fertil Steril 2008; 89: 458-67. https://doi.org/10.1016/j.fertnstert.2007.02.058
  14. Doody KJ, Schnell VL, Foulk RA, Miller CE, Kolb BA, Blake EJ, et al. Endometrin for luteal phase support in a randomized, controlled, open label, prospective IVF clinical trial using a combination of menopur and bravelle. Fertil Steril 2009; 91: 1012-7. https://doi.org/10.1016/j.fertnstert.2008.01.069
  15. Zarutskie PW, Phillips JA. A meta-analysis of the route of administration of luteal phase support in assisted reproductive technology: vaginal versus intramuscular progesterone. Fertil Steril 2009; 92: 163-9. https://doi.org/10.1016/j.fertnstert.2009.02.018
  16. Hubayter ZR, Muasher SJ. Luteal supplementation in in vitro fertilization: more questions than answers. Fertil Steril 2008; 89: 749-58. https://doi.org/10.1016/j.fertnstert.2008.02.095
  17. Iwase A, Ando H, Toda S, Ishimatsu S, Harata T, Kurotsuchi S, et al. Oral progestogen versus intramuscular progesterone for luteal support after assisted reproductive technology treatment: a prospective randomized study. Arch Gynecol Obstet 2008; 277: 319-24. https://doi.org/10.1007/s00404-007-0484-4
  18. Licciardi FL, Kwiatkowski A, Noyes NL, Berkeley AS, Krey LL, Grifo JA. Oral versus intramuscular progesterone for in vitro fertilization: a prospective randomized study. Fertil Steril 1999; 71: 614-8. https://doi.org/10.1016/S0015-0282(98)00515-9
  19. Lee JR, Kim SH, Kim SM, Jee BC, Ku SY, Suh CS, et al. Follicular fluid anti-Müllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist cycles. Fertil Steril 2008; 89: 860-7. https://doi.org/10.1016/j.fertnstert.2007.04.010
  20. Costabile L, Gerli S, Manna C, Rossetti D, Di Renzo GC, Unfer V. A prospective randomized study comparing intramuscular progesterone and 17alpha-hydroxyprogesterone caproate in patients undergoing in vitro fertilization-embryo transfer cycles. Fertil Steril 2001; 76: 394-6. https://doi.org/10.1016/S0015-0282(01)01901-X
  21. Lightman A, Kol S, Itskovitz-Eldor J. A prospective randomized study comparing intramuscular with intravaginal natural progesterone in programmed thaw cycles. Hum Reprod 1999; 14: 2596-9. https://doi.org/10.1093/humrep/14.10.2596
  22. Bouckaert Y, Robert F, Englert Y, De Backer D, De Vuyst P, Delbaere A. Acute eosinophilic pneumonia associated with intramuscular administration of progesterone as luteal phase support after IVF: case report. Hum Reprod 2004; 19: 1806 -10 https://doi.org/10.1093/humrep/deh316
  23. Veysman B, Vlahos I, Oshva L. Pneumonitis and eosinophilia after in vitro fertilization treatment. Ann Emerg Med 2006; 47: 472-5. https://doi.org/10.1016/j.annemergmed.2005.12.023
  24. Smitz J, Erard P, Camus M, Devroey P, Tournaye H, Wisanto A, et al. Pituitary gonadotrophin secretory capacity during the luteal phase in superovulation using GnRH-agonists and HMG in a desensitization or flare-up protocol. Hum Reprod 1992; 7: 1225-9. https://doi.org/10.1093/oxfordjournals.humrep.a137831
  25. Smitz J, Bourgain C, Van Waesberghe L, Camus M, Devroey P, Van Steirteghem AC. A prospective randomized study on estradiol valerate supplementation in addition to intravaginal micronized progesterone in buserelin and HMG-induced superovulation. Hum Reprod 1993; 8: 40-5. https://doi.org/10.1093/oxfordjournals.humrep.a137871
  26. Beckers NG, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum RE, Diedrich K, et al. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant folliclestimulating hormone and GnRH antagonist cotreatment. J Clin Endocrinol Metab 2003; 88: 4186-92. https://doi.org/10.1210/jc.2002-021953
  27. Buvat J, Marcolin G, Guittard C, Herbaut JC, Louvet AL, Dehaene JL. Luteal support after luteinizing hormonereleasing hormone agonist for in vitro fertilization: superiority of human chorionic gonadotropin over oral progesterone. Fertil Steril 1990; 53: 490-4. https://doi.org/10.1016/S0015-0282(16)53346-9
  28. Pouly JL, Bassil S, Frydman R, Hedon B, Nicollet B, Prada Y, et al. Luteal support after in-vitro fertilization: Crinone 8%, a sustained release vaginal progesterone gel, versus Utrogestan, an oral micronized progesterone. Hum Reprod 1996; 11: 2085-9. https://doi.org/10.1093/oxfordjournals.humrep.a019054
  29. Chakravarty BN, Shirazee HH, Dam P, Goswami SK, Chatterjee R, Ghosh S. Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study. J Steroid Biochem Mol Biol 2005; 97: 416-20. https://doi.org/10.1016/j.jsbmb.2005.08.012
  30. Friedler S, Raziel A, Schachter M, Strassburger D, Bukovsky I, Ron-El R. Luteal support with micronized progesterone following in-vitro fertilization using a down-regulation protocol with gonadotrophin-releasing hormone agonist: a comparative study between vaginal and oral administration. Hum Reprod 1999; 14: 1944-8. https://doi.org/10.1093/humrep/14.8.1944
  31. Patki A, Pawar VC. Modulating fertility outcome in assisted reproductive technologies by the use of dydrogesterone. Gynecol Endocrinol 2007; 23 Suppl 1: 68-72. https://doi.org/10.1080/09513590701584857
  32. Ludwig M, Schwartz P, Babahan B, Katalinic A, Weiss JM, Felberbaum R, et al. Luteal phase support using either Crinone 8% or Utrogest: results of a prospective, randomized study. Eur J Obstet Gynecol Reprod Biol 2002; 103: 48-52. https://doi.org/10.1016/S0301-2115(02)00010-6
  33. Ng EH, Miao B, Cheung W, Ho PC. A randomised comparison of side effects and patient inconvenience of two vaginal progesterone formulations used for luteal support in in vitro fertilisation cycles. Eur J Obstet Gynecol Reprod Biol 2003; 111: 50-4. https://doi.org/10.1016/S0301-2115(03)00156-8
  34. Scott R, Navot D, Liu HC, Rosenwaks Z. A human in vivo model for the luteoplacental shift. Fertil Steril 1991; 56: 481-4. https://doi.org/10.1016/S0015-0282(16)54544-0
  35. Jarvelä IY, Ruokonen A, Tekay A. Effect of rising hCG levels on the human corpus luteum during early pregnancy. Hum Reprod 2008; 23: 2775-81. https://doi.org/10.1093/humrep/den299
  36. Mochtar MH, Van Wely M, Van der Veen F. Timing luteal phase support in GnRH agonist down-regulated IVF/embryo transfer cycles. Hum Reprod 2006; 21: 905-8. https://doi.org/10.1093/humrep/dei437
  37. Nyboe Andersen A, Popovic-Todorovic B, Schmidt KT, Loft A, Lindhard A, Hojgaard A, et al. Progesterone supplementation during early gestations after IVF or ICSI has no effect on the delivery rates: a randomized controlled trial. Hum Reprod 2002; 17: 357-61. https://doi.org/10.1093/humrep/17.2.357
  38. Zinaman MJ, Clegg ED, Brown CC, O'Connor J, Selevan SG. Estimates of human fertility and pregnancy loss. Fertil Steril 1996; 65: 503-9. https://doi.org/10.1016/S0015-0282(16)58144-8
  39. Ellish NJ, Saboda K, O'Connor J, Nasca PC, Stanek EJ, Boyle C. A prospective study of early pregnancy loss. Hum Reprod 1996; 11: 406-12. https://doi.org/10.1093/HUMREP/11.2.406
  40. Tong S, Kaur A, Walker SP, Bryant V, Onwude JL, Permezel M. Miscarriage risk for asymptomatic women after a normal first-trimester prenatal visit. Obstet Gynecol 2008; 111: 710-4.